SK157899A3 - Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions - Google Patents

Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions Download PDF

Info

Publication number
SK157899A3
SK157899A3 SK1578-99A SK157899A SK157899A3 SK 157899 A3 SK157899 A3 SK 157899A3 SK 157899 A SK157899 A SK 157899A SK 157899 A3 SK157899 A3 SK 157899A3
Authority
SK
Slovakia
Prior art keywords
preparation
pharmaceutical compositions
kinase inhibitors
substituted pyrazoles
pyrazoles
Prior art date
Application number
SK1578-99A
Other languages
English (en)
Slovak (sk)
Inventor
Ashok Anantanarayan
Michael Clare
Paul W Collins
Zuowu Joyce Crich
Rajesh Devraj
Daniel L Flynn
Lifeng Geng
Gunnar J Hanson
Francis J Koszyk
Shuyuan Liao
Richard A Partis
Shashidhar N Rao
Raj Shaun Selness
Michael S South
Michael A Stealey
Richard M Weier
Xiangdong Xu
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of SK157899A3 publication Critical patent/SK157899A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SK1578-99A 1997-05-22 1998-05-22 Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions SK157899A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4757097P 1997-05-22 1997-05-22
PCT/US1998/010436 WO1998052940A1 (en) 1997-05-22 1998-05-22 SUBSTITUTED PYRAZOLES AS p38 KINASE INHIBITORS

Publications (1)

Publication Number Publication Date
SK157899A3 true SK157899A3 (en) 2000-08-14

Family

ID=21949743

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1578-99A SK157899A3 (en) 1997-05-22 1998-05-22 Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions

Country Status (24)

Country Link
EP (1) EP1000055A1 (xx)
JP (1) JP2002508754A (xx)
KR (1) KR20010012854A (xx)
CN (1) CN1264377A (xx)
AP (1) AP1246A (xx)
AU (1) AU754830C (xx)
BG (1) BG64313B1 (xx)
BR (1) BR9809147A (xx)
CA (1) CA2291115A1 (xx)
EA (1) EA003925B1 (xx)
EE (1) EE9900527A (xx)
GE (1) GEP20033053B (xx)
HU (1) HUP0001880A3 (xx)
ID (1) ID22982A (xx)
IL (1) IL132991A (xx)
IS (1) IS5257A (xx)
NO (1) NO995695L (xx)
NZ (1) NZ501112A (xx)
OA (1) OA12981A (xx)
PL (1) PL337020A1 (xx)
SK (1) SK157899A3 (xx)
TR (1) TR200000235T2 (xx)
WO (1) WO1998052940A1 (xx)
ZA (1) ZA984358B (xx)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW289752B (xx) * 1994-03-11 1996-11-01 Ciba Geigy Ag
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
WO1998056377A1 (en) 1997-06-13 1998-12-17 Smithkline Beecham Corporation Novel pyrazole and pyrazoline substituted compounds
US7301021B2 (en) 1997-07-02 2007-11-27 Smithkline Beecham Corporation Substituted imidazole compounds
US6184226B1 (en) * 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
EP1119254A4 (en) 1998-10-07 2004-05-12 Smithkline Beecham Corp STROKE TREATMENT
JP4634613B2 (ja) 1998-12-16 2011-02-16 アベンティス・フアーマ・リミテッド ヘテロアリール環状アセタール類
US6191147B1 (en) 1998-12-24 2001-02-20 Ppd Discovery, Inc. Pyrazole compounds and uses thereof
JP4632544B2 (ja) * 1998-12-25 2011-02-16 あすか製薬株式会社 アミノピラゾール誘導体
DE60044395D1 (de) 1999-03-26 2010-06-24 Euro Celtique Sa Arylsubstituierte pyrazole, imidazole, oxazole, thiazole und pyrrole, sowie deren verwendung
US6667325B1 (en) 1999-06-03 2003-12-23 Teikoku Hormone Mfg. Co., Ltd. Substituted pyrazole compounds
US7122666B2 (en) 1999-07-21 2006-10-17 Sankyo Company, Limited Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses
EP1218369B1 (en) * 1999-08-13 2008-07-23 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES
WO2001030154A2 (de) * 1999-10-25 2001-05-03 Basf Aktiengesellschaft Pyrazole enthaltende agrochemische zusammensetzungen und ihre verwendung als fungizide flanzenschutzmittel
DE19952147A1 (de) 1999-10-29 2001-05-03 Boehringer Ingelheim Pharma Neue Cyclopropane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
AU1781601A (en) 1999-11-23 2001-06-04 Smithkline Beecham Corporation 3,4-dihydro-(1h)quinazolin-2-one compounds as csbp/p38 kinase inhibitors
JP4911864B2 (ja) 2000-08-14 2012-04-04 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 置換ピラゾール
GB0102687D0 (en) 2001-02-02 2001-03-21 Pharmacia & Upjohn Spa Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them
WO2002062792A1 (fr) * 2001-02-02 2002-08-15 Takeda Chemical Industries, Ltd. Inhibiteur de jnk
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
DK1397364T3 (da) 2001-05-24 2007-11-26 Lilly Co Eli Hidtil ukendte pyrrolderivater som farmaceutiske midler
KR100697482B1 (ko) 2001-09-25 2007-03-20 파마시아 코포레이션 치환된 피라졸의 제조 방법
US7057049B2 (en) 2001-09-25 2006-06-06 Pharmacia Corporation Process for making substituted pyrazoles
JP2005538958A (ja) * 2002-06-05 2005-12-22 ファルマシア・コーポレーション ｐ３８キナーゼ阻害薬としてのピラゾール誘導体
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004004725A2 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
GB0217786D0 (en) * 2002-07-31 2002-09-11 Glaxo Group Ltd Compounds
US7166619B2 (en) 2002-08-14 2007-01-23 Ppd Discovery , Inc. Prenylation inhibitors and methods of their synthesis and use
US6649638B1 (en) 2002-08-14 2003-11-18 Ppd Discovery, Inc. Prenylation inhibitors and methods of their synthesis and use
AU2003268155A1 (en) * 2002-09-19 2004-04-08 Eli Lilly And Company Methods of inhibiting tgf beta with substituted pyrazoles
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
EP1591443B1 (en) 2003-02-07 2010-08-25 Daiichi Sankyo Company, Limited Pyrazole derivative
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
AP2326A (en) 2004-08-12 2011-11-24 Pfizer Triazolopyridinylsulfanyl derivatives as p38 map kinase inhibitors.
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
CA2591912C (en) 2004-12-28 2013-06-25 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazole derivatives
WO2007105058A2 (en) * 2006-03-16 2007-09-20 Pfizer Products Inc. Pyrazole compounds
WO2008001929A1 (fr) * 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Agent de traitement pour la maladie intestinale inflammatoire
AU2007265965B2 (en) 2006-06-28 2012-03-08 Aska Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
CN101610754A (zh) 2007-02-16 2009-12-23 Aska制药株式会社 含有微粒油性混悬液的药物组合物
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
EP2181110A2 (en) * 2007-07-13 2010-05-05 ADDEX Pharma S.A. Novel heteroaromatic derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors
AR069545A1 (es) 2007-11-16 2010-02-03 Boehringer Ingelheim Pharma Derivados de aril y heteroarilcarbonilo de benzomorfanos y estructuras relacionadas, composiciones farmaceuticas que contienen dichos compuestos, obtencion de las mismas, su uso en el tratamiento de enfermedades mediadas por la inhibicion de la enzima 11beta-hidroxiesteroide deshidrogenasa (hsd) 1 y
CL2009000904A1 (es) * 2008-04-21 2010-04-30 Shionogi & Co Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
AR071719A1 (es) 2008-05-13 2010-07-07 Boehringer Ingelheim Int Derivados aliciclicos de acido carboxilico de benzomorfanos y estructuras relacionadas, medicamentos que contienen dichos compuestos y su uso.procesos de obtencion
EP2324008B1 (en) 2008-07-24 2012-05-09 Nerviano Medical Sciences S.R.L. 3,4-diarylpyrazoles as protein kinase inhibitors
WO2010023161A1 (en) * 2008-08-25 2010-03-04 Boehringer Ingelheim International Gmbh Aryl- and heteroarylcarbonyl derivatives of substituted nortropanes, medicaments containing such compounds and their use
JP2012506388A (ja) * 2008-10-23 2012-03-15 ロンザ リミテッド 置換されたピラゾールの合成方法
WO2010058858A1 (ja) * 2008-11-21 2010-05-27 ラクオリア創薬株式会社 ５－ｈｔ２ｂ受容体拮抗活性を有する新規ピラゾール－３－カルボキサミド誘導体
JP5670440B2 (ja) 2009-06-02 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング １１β−ヒドロキシステロイドデヒドロゲナーゼ１の環状阻害剤
US8927539B2 (en) 2009-06-11 2015-01-06 Vitae Pharmaceuticals, Inc. Cyclic inhibitors of 11β-hydroxysteroid dehydrogenase 1 based on the 1,3-oxazinan-2-one structure
JP2013503129A (ja) * 2009-08-26 2013-01-31 ノバルティス アーゲー テトラ−置換ヘテロアリール化合物ならびにｍｄｍ２および／またはｍｄｍ４モジュレーターとしてのそれらの使用
AR077975A1 (es) 2009-08-28 2011-10-05 Irm Llc Derivados de pirazol pirimidina y composiciones como inhibidores de cinasa de proteina
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
AR079545A1 (es) 2009-12-21 2012-02-01 Bayer Cropscience Ag Tienilpiri(mi)dinilazol
KR20120133377A (ko) 2010-01-27 2012-12-10 네르비아노 메디칼 사이언시스 에스.알.엘. 단백질 키나아제 억제제로서 3,4-디아릴피아졸의 설폰아미도 유도체
AR081810A1 (es) 2010-04-07 2012-10-24 Bayer Cropscience Ag Piridinilpirazoles biciclicos
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
WO2012016993A1 (en) 2010-08-03 2012-02-09 Nerviano Medical Sciences S.R.L. Derivatives of pyrazolophenyl-benzenesulfonamide compounds and use thereof as antitumor agents
EP2654750B1 (en) * 2010-12-20 2017-03-08 Pfizer Inc Novel fused pyridine compounds as casein kinase inhibitors
AR086992A1 (es) 2011-06-20 2014-02-05 Bayer Ip Gmbh Tienilpiri(mi)dinilpirazoles
JP2014524438A (ja) 2011-08-17 2014-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング インデノピリジン誘導体
RU2627272C2 (ru) 2011-10-06 2017-08-04 Байер Интеллектчуал Проперти Гмбх Гетероциклилпиридинилпиразолы
BR112014008223A2 (pt) 2011-10-06 2017-04-25 Bayer Ip Gmbh heterociclilpiri (mi) dinilpirazol
DE102011115525A1 (de) 2011-10-11 2013-04-11 Boehringer Ingelheim International Gmbh Zweiteilige Flasche mit einem darin angeordneten Trockenmittel
CN108542906A (zh) 2011-11-11 2018-09-18 诺华股份有限公司 治疗增生性疾病的方法
SG11201401260QA (en) 2011-11-23 2014-07-30 Novartis Ag Pharmaceutical formulations
US9452170B2 (en) 2013-03-15 2016-09-27 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
BR112016012482B1 (pt) * 2013-12-12 2020-07-21 Sumitomo Chemical Company, Limited composto aromático, seu uso, agente e método de controle de peste
CN104829536B (zh) * 2015-05-04 2017-12-29 陕西科技大学 一种具抗肿瘤活性的苯基吡唑羧酸类化合物及其合成方法
CN107848962B (zh) * 2015-05-27 2021-04-09 杏林制药株式会社 脲衍生物或其药理学上可接受的盐
CN112480079B (zh) * 2017-11-08 2022-03-11 北京嘉林药业股份有限公司 化合物及其治疗癌症的用途
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. PYRROLE AND PYRAZOLE COMPOUNDS AND METHODS OF USE THERE
AU2020417293A1 (en) 2020-01-03 2022-09-01 Berg Llc Polycyclic amides as UBE2K modulators for treating cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5559137A (en) * 1994-05-16 1996-09-24 Smithkline Beecham Corp. Compounds
US5486534A (en) * 1994-07-21 1996-01-23 G. D. Searle & Co. 3,4-substituted pyrazoles for the treatment of inflammation

Also Published As

Publication number Publication date
IL132991A0 (en) 2001-03-19
CA2291115A1 (en) 1998-11-26
BG103964A (en) 2000-08-31
PL337020A1 (en) 2000-07-31
WO1998052940A1 (en) 1998-11-26
NZ501112A (en) 2002-10-25
ID22982A (id) 1999-12-23
EE9900527A (et) 2000-06-15
BG64313B1 (bg) 2004-09-30
EA199900953A1 (ru) 2000-10-30
AP9901715A0 (en) 1999-12-31
KR20010012854A (ko) 2001-02-26
IL132991A (en) 2005-11-20
NO995695D0 (no) 1999-11-19
AU754830B2 (en) 2002-11-28
OA12981A (en) 2006-10-13
BR9809147A (pt) 2000-08-01
AU7588398A (en) 1998-12-11
JP2002508754A (ja) 2002-03-19
ZA984358B (en) 1999-05-24
HUP0001880A2 (en) 2001-03-28
HUP0001880A3 (en) 2002-03-28
EA003925B1 (ru) 2003-10-30
NO995695L (no) 2000-01-21
EP1000055A1 (en) 2000-05-17
TR200000235T2 (tr) 2000-05-22
AP1246A (en) 2004-02-07
AU754830C (en) 2004-02-12
GEP20033053B (en) 2003-08-25
CN1264377A (zh) 2000-08-23
IS5257A (is) 1999-11-19

Similar Documents

Publication Publication Date Title
SK157899A3 (en) Substituted pyrazoles as p38 kinase inhibitors, process for their preparation and pharmaceutical compositions
HUP0200130A2 (en) Substituted pyrazoles as p38 kinase inhibitors and pharmaceutical compositions containing them
HUP0400908A3 (en) Pyrazole compounds useful as protein kinase inhibitors, their use and pharmaceutical compositions containing them
AU3859999A (en) 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
HUP0101581A3 (en) Pyrazole derivatives as p-38 map kinase inhibitors, the pharmaceutical compositions containing the same, process for their preparation and their use
HUP0200355A2 (en) 4-aminopyrrolopyrimidines as kinase inhibitors, pharmaceutical compositions containing them and their use
IL153997A0 (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
HUP0401819A3 (en) Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
IL146710A0 (en) Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
AU7726898A (en) Pyrazole derivatives as p38 kinase inhibitors
HUP0202682A3 (en) Tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
HUP0202708A3 (en) Cyclic protein tyrosine kinase inhibitors, pharmaceutical compositions containing them and their use
NO973479L (no) Substituerte heterosykliske forbindelser, fremgangsmåte for fremstilling og farmasöytiske blandinger inneholdende samme
HUP0004490A2 (en) Substituted oxindole derivatives as protein tyrosine kinase and as protein serine/threoning kinase inhibitors and pharmaceutical compositions containing them
EE200000651A (et) Asoolid, nende valmistamismeetod, kasutamine ja farmatseutiline kompositsioon
AU1189201A (en) Therapeutic compositions including protein kinase c inhibitors
AU2003200580A1 (en) Substituted pyrazoles as P38 kinase inhibitors